

International Society for the Study of Xenobiotics

[View the current International Society for the Study of Xenobiotics Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/24932-International+Society+for+the+Study+of+Xenobiotics.html)

(<http://www.bioportfolio.com/biocorporate/24932-International+Society+for+the+Study+of+Xenobiotics.html>)

Contact Details:

2025 M Street, NW, Suite 800

Washington

District of Columbia

20036

United States of America

Tel: 1-202-367-1160

Fax: 1-202-367-2160

Email: information@issx.org

Man's use of xenobiotics dates from antiquity but interest in foreign compound metabolism dates from only the mid-19th century when the knowledge and techniques of organic chemistry were first applied to its study. For nearly a century thereafter biotransformation was generally equated with "detoxication" or the elimination of a compound's biological activity. This view changed in the late 1930s with the discovery that the synthetic azo-dye Prontosil owed its life-saving antibacterial activity to its metabolite, sulfanilamide. Since the 1950s the biological effects of numerous xenobiotic substances have been shown to be due to biotransformation products rather than the parent compound. The importance of biotransformation and other aspects of the interaction of xenobiotics with living systems has not escaped the notice of regulatory agencies worldwide. Their need for scientific knowledge on which to base regulations and safety evaluations for chemicals and drugs provides one important motivation for the study of xenobiotics. Of necessity, scientists working in such diverse fields as clinical and basic pharmacology, biochemistry, toxicology and oncology became drawn into metabolism studies, both in universities and research institutes and in the pharmaceutical, chemical, agro-chemical, food processing, tobacco and cosmetic industries. In 1981, a small group of scientists, brought together during the 1970s under the aegis of the Gordon Research Conferences on Drug Metabolism, took the bold step of suggesting the organization of an international society to promote the interaction of scientists dedicated broadly to the study of xenobiotics in living systems. Thus the International Society for the Study of Xenobiotics was formed.

Press Releases on International Society for the Study of Xenobiotics:

River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries	21st November, 2009	American Society of Tropical Medicine and Hygiene	WASHINGTON, Nov. 21 /PRNewswire-USNewswire/ -- A regional initiative launched in the 1990s to eliminate onchocerciasis (river blindness) in the Americas has substantially reduced the prevalence of the
ASTMH Symposium Showcases Efforts To Meet the Need for New Medicines to Treat Infectious Diseases in Developing Countries	21st November, 2009	The American Society of Tropical Medicine and Hygiene	-- Extending a Hand: Eli Lilly's TB Drug Discovery Partnership -- Gail H. Cassell, Eli Lilly & Co., Indianapolis, IN The aim of the symposium was to illustrate how industry
Veridiam Wins Workplace Excellence Crystal Award in Mid-Size Company Category	20th November, 2009	Veridiam	SAN DIEGO, Nov. 20 /PRNewswire/ -- Veridiam (www.veridiam.com) won the prestigious Crystal Award in the mid-size company category at the 2009 Workplace Excellence Awards. The awards are sponsored by
Counselors Address Mental-Health Crisis in Developing Countries	20th November, 2009	Wake Forest University	WINSTON-SALEM, N.C., Nov. 20 /PRNewswire-USNewswire/ -- Worldwide, more than 450 million people live with unmet mental health care needs. Wake Forest University Counseling Professor Donna Henderson co
Case Studies Offer Inside Look at Effective Ways to Address Global Health Challenges	20th November, 2009	Alliance for Case Studies for Global Health	Publication to Serve as Guide to Understanding, Building Productive Partnerships WASHINGTON, Nov. 20 /PRNewswire-USNewswire/ -- Meaningful and lasting progress in addressing global health challenges

BioNews Results for International Society for the Study of Xenobiotics



- [Transparent Inc. To Introduce Cell-able, A Unique Human Hepatocyte Array, To U.S. Market At ISSX Meeting](#)
Drug Discovery Online: Oct 19 2009 2:15PM Matching: international society study xenobiotics
- [Transparent Inc. To Introduce Cell-able, A Unique Human Hepatocyte Array, To U.S. Market At ISSX Meeting](#)
Pharmaceutical Online: Oct 19 2009 12:52PM Matching: international society study xenobiotics
- [Transparent to introduce Cell-able in US](#)
Bio Spectrum Asia: Oct 14 2009 9:59AM Matching: international society study xenobiotics
- [Transparent Inc. To Introduce Cell-Able, A Unique Human Hepatocyte Array, To U.S. Market At ISSX Meeting](#)

BioSpace: Oct 14 2009 5:45AM Matching: international society study xenobiotics

- [Transparent Inc. to Introduce Cell-able, a Unique Human Hepatocyte Array, to U.S. Market at ISSX Meeting](#)

Freshnews.com: Oct 13 2009 3:22PM Matching: international society study xenobiotics

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

